Delivery Order SPE2DB24D2018-SPE2DB25FWWU2
- Not listed
- The Defense Logistics Agency awarded a $32,161.80 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This is a firm fixed-price contract with a completion deadline of September 12, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $7,625.80. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $7,403.76 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 14, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,836.37 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. This competitive award utilizes firm fixed pricing and requires completion by July 21, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.56 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWU2Delivery Order
The Defense Logistics Agency awarded a $64,579.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with an ultimate completion date of September 18, 2025. This non-competitive delivery order represents a single-line pharmaceutical procurement issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as one of the nation's largest pharmaceutical distributors. AmerisourceBergen Drug Corp serves as a critical supplier within the Defense Health Agency's medical supply chain, providing a comprehensive portfolio of pharmaceutical products and medical supplies to support military healthcare systems globally. As a major pharmaceutical distributor and healthcare solutions provider, the company has demonstrated consistent capability to fulfill federal procurement requirements through open competition. The delivery of Zepbound, a GLP-1 receptor agonist used for weight management, aligns with the company's established role in supplying specialty medications and brand-name pharmaceuticals to support the broad therapeutic needs of military and federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $64.6k | 9/17/25 |